Group 1: Company Insights - E Fund recently conducted research on seven listed companies, highlighting significant growth in revenue for Yuanjie Technology, particularly in the demand for 400G/800G optical modules, with expectations for substantial growth in the second half of 2025 [1] - Weisi Medical's lower limb exoskeleton device has been included in the medical insurance directory, and its electrical stimulation products are primarily used in obstetrics and gynecology departments [1] - Dekoli experienced rapid growth in computing power demand but faced challenges with capacity and supply chain resources, leading to insufficient order fulfillment [1] - Ningbo Jingda's performance was slightly impacted by international trade factors, but it saw a double-digit growth in orders in the second quarter, with a 70% increase in export orders after acquiring Wuxi Micro Research [2] - Xinmai Medical reported a revenue of 714 million yuan and a net profit of 315 million yuan, with overseas revenue growing over 95% [3] - Kehua Data achieved a revenue of 3.733 billion yuan, with a 0.06% year-on-year growth, and a 16.77% increase in data center business revenue [4] Group 2: Industry Trends - The demand for high-power CW light sources and high-speed EML technology is increasing, with companies focusing on core technology breakthroughs and maintaining high gross profit margins [1] - The integration of advanced technologies in manufacturing, such as high-frequency pipe-making and rolling machines, is being pursued to promote import substitution in the industry [2] - The development of new energy solutions, including 2000V450kW inverters, is being accelerated to serve various sectors, including state-owned enterprises [3] - The semiconductor industry is facing challenges with high R&D investments and increased financial costs, impacting profitability for companies like Dongxin [5]

Group 1: Company Insights - Yuanjie Technology reported significant revenue growth in the data communication sector, particularly for 400G/800G optical modules, with expectations for substantial growth in the second half of 2025 [1] - Huafeng Measurement Control experienced a 41% year-on-year revenue increase in the semiconductor industry, with a notable 37.6% growth in net profit, driven by stable demand in power devices and consumer electronics [2] - Dekeli faced challenges in order delivery due to insufficient capacity and supply chain resources, but anticipates improvement with new facilities coming online in the second half of 2025 [3] - Kebo Da achieved a revenue of 3.047 billion yuan, an 11.1% increase year-on-year, with a net profit of 451 million yuan, reflecting a 21.34% growth [4] - Ningbo Jingda's performance was slightly impacted by international trade factors, but saw a recovery in the second quarter with a 70% increase in export orders [5] - Jinbo Co. reported a 19.69% increase in revenue to 411 million yuan, with significant growth in new business areas, particularly in the lithium battery sector [6] - Xinmai Medical achieved a revenue of 714 million yuan and a net profit of 315 million yuan, with overseas revenue growing over 95% [7] - Guangxun Technology's revenue is expected to continue growing, with a historical peak in silicon optical module shipments and plans to adjust production capacity based on market demand [8] Group 2: Industry Trends - The semiconductor industry is expected to continue its recovery trend into 2025, with increasing demand for data centers and power devices [2] - The demand for optical communication products is anticipated to grow, particularly with the introduction of 400G and 800G technologies [1][8] - The automotive sector is seeing a shift towards energy management products and lightweight solutions, with companies exploring new directions in EV and hydrogen energy [5] - The overall market for optical communication is projected to remain stable in the second half of 2025, with a focus on MEMS technology for OCS products [8]

调研纪要：报告期内，公司实现营业收入7.14亿元，净利润3.15亿元，拟每10股派现13.00元(含税)，总 额1.57亿元。Cratos于3月国内上市，挂网价低于10万元，推广进度超预期；Hector获欧盟定制证书，在 欧洲多国完成临床植入，获医生认可。研发投入预计今年约10%，未来维持在10%-15%。海外收入同比 增长超95%，占比达17%，主因并表Lombard及自身增长，覆盖45国，计划明年达60国。Talos、 Cratos、Fontus等高毛利产品将陆续出海。 恒生前海基金成立于2016年，截至目前，资产管理规模(全部公募基金)164.7亿元，排名126/210；资产 管理规模(非货币公募基金)164.68亿元，排名109/210；管理公募基金数54只，排名100/210；旗下公募基 金经理7人，排名126/210。旗下最近一年表现最佳的公募基金产品为恒生前海高端制造混合A，最新单 位净值为0.96，近一年增长89.37%。旗下最新募集公募基金产品为恒生前海瑞丰混合A，类型为混合型- 偏股，集中认购期2025年8月18日至2025年9月5日。 1)心脉医疗(恒生前海基金参与公司2025年半年度业 ...

Group 1: Dekoli - The company is experiencing rapid growth in computing power demand, but faces challenges with insufficient production capacity and supply chain resources, leading to order delivery issues [1] - Revenue from data communication products is increasing, with access and data products accounting for nearly 40% of total revenue; however, telecom business revenue has decreased by approximately 8% year-on-year [1] - A new factory is expected to be operational in the second half of the year, which is anticipated to improve the situation; OCS products have received orders worth millions [1] - The company's factory in Thailand is projected to start production after the 2026 Spring Festival, with some clients already certified [1] - The company emphasizes enhancing core competitiveness to address uncertainties in tariff policies [1] Group 2: Xinmai Medical - The company reported a revenue of 714 million yuan and a net profit of 315 million yuan during the reporting period, with a proposed cash dividend of 1.3 yuan per share, totaling 157 million yuan [1] - The Cratos product was launched domestically in March, with a listing price below 100,000 yuan, and its promotion is exceeding expectations; Hector has received custom certification in the EU and has completed clinical implants in multiple countries [1] - Research and development investment is expected to be around 10% this year, maintaining a range of 10%-15% in the future [1] - Overseas revenue has increased by over 95% year-on-year, accounting for 17% of total revenue, primarily due to the consolidation of Lombard and organic growth, with plans to expand coverage from 45 to 60 countries next year [1] - High-margin products such as Talos, Cratos, and Fontus are set to be launched internationally [1] Group 3: Green Fund - Green Fund was established in 2016, with total assets under management of 25.643 billion yuan, ranking 110 out of 210 in public funds [2] - The fund has 61 public funds under management, ranking 91 out of 210, and employs 12 fund managers, ranking 97 out of 210 [2] - The best-performing public fund product in the past year is the Green High Dividend Preferred Mixed A, with a latest net value of 1.84 and a growth of 118.24% over the past year [2] - The latest public fund product launched is the Green Technology Growth Mixed A, which is equity-oriented and has a subscription period from August 8, 2025, to November 7, 2025 [2]